# OnCo record idelalisib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/idelalisib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "idelalisib" ;
  schema:name "Idelalisib"@en ;
  schema:description "Idelalisib was the first PI3K inhibitor for blood cancers; it is effective in CLL with rituximab but so toxic (colitis, hepatitis, pneumonitis, infections) that the class has largely been abandoned."@en ;
  schema:url <https://onco.cc/drugs/idelalisib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Idelalisib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q5908266> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=idelalisib> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule PI3Kδ inhibitor" ;
  schema:alternateName "Zydelig" ;
  onco:approval "US 2014: Relapsed CLL with rituximab; relapsed FL and SLL (accelerated, withdrawn 2022)", "EU 2014: CLL, FL" ;
  onco:acceleratedApproval "US 2014-07-23: For the treatment of relapsed follicular B-cell Non-Hodgkin Lymphoma (FL) in patients who have received at least 2 prior systemic therapies and relapsed small lymphocytic lymphoma (SLL) in patients who have received at least 2 prior systemic therapies" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/cll-relapsed/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/pik3ca/> ;
  onco:companies <https://onco.cc/companies/gilead/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:trials <https://onco.cc/trials/nct06846671/>, <https://onco.cc/trials/nct02970318/> .